Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Oncoscience|August 6, 2015
Targeting CD44 as a novel therapeutic approach for treating pancreatic cancer recurrenceMaria Inés Molejon, Juan Ignacio Tellechea, Vincent Moutardier, et al.
Endoscopy International Open|August 27, 2021
Long-term outcome after EUS-guided radiofrequency ablation: Prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasmsMarc Barthet, Marc Giovannini, Mohamed Gasmi, et al.
Cancer Medicine|May 2, 2013
Expression of adrenomedullin in human colorectal tumors and its role in cell growth and invasion in vitro and in xenograft growth in vivoEmilie Nouguerède, Caroline Berenguer, Stéphane Garcia, et al.
BMC Cancer|November 29, 2011
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancerLaetitia Dahan, Emmanuelle Norguet, Marie-Christine Etienne-Grimaldi, et al.
Langenbeck'S Archives of Surgery|June 20, 2024
Surgical versus endoscopic gastroenterostomy for gastric outlet obstruction: a retrospective multicentric comparative study of technical and clinical successEugénie Martinet, Jean-Michel Gonzalez, Maxime Thobois, et al.
Surgical Endoscopy|June 8, 2026
Choledochoduodenostomy versus transpapillary stent by endoscopic retrograde cholangiopancreatography for preoperative biliary drainage before pancreatoduodenectomy: a French multicenter retrospective cohort studyNadiya Belfil, Shani Diai, Jean-Michel Gonzalez, et al.
Endoscopy|June 28, 2023
Endoscopic ultrasound-guided gastroenterostomy with lumen-apposing metal stents: a retrospective multicentric comparison of wireless and over-the-wire techniquesLaurent Monino, Enrique Perez-Cuadrado-Robles, Jean-Michel Gonzalez, et al.
Oncotarget|March 24, 2015
Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinomaMaria Inés Molejon, Juan Ignacio Tellechea, Celine Loncle, et al.
Gut|October 16, 2010
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)Laetitia Dahan, Frank Bonnetain, Marc Ychou, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|February 12, 2019
Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trialBenjamin Lacas, Olivier Bouché, Pierre-Luc Etienne, et al.
Pageof 5